Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 19/20 | 0.63 |
| ▸ | NSD2 | O96028 | 3/20 | 0.63 |
| ▸ | NSD3 | Q9BZ95 | 3/20 | 0.63 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.63 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430299 | 0.97 | EHMT2 (0.65) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL1427845 | 0.97 | EHMT2 (0.58) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL1428062 | 0.93 | EHMT2 (0.59) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL4198293 | 0.91 | EHMT2 (0.53) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL1427885 | 0.88 | EHMT2 (0.62) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL1427508 | 0.87 | EHMT2 (0.51) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL9911843 | 0.86 | EHMT2 (0.59) | EHMT2EZH2KDM1ADNMT3A | |
| SCHEMBL1428356 | 0.85 | NSD2 (0.54) | EHMT2NSD2EZH2KDM1A | |
| SCHEMBL4195120 | 0.85 | EHMT2 (0.48) | EHMT2NSD2NSD3EHMT1EZH2 | |
| SCHEMBL1427882 | 0.84 | EHMT2 (0.72) | EHMT2NSD2NSD3EHMT1EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-102105463-A | Bicyclic compounds active on the CXCR4 receptor | ALLERGAN INC | 2011-06-22 | — | — | CN | disclosed |
| EP-2300456-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | Allergan, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009143058-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | CXCR4, CXCR2, CXCL12 | EHMT2 4669/4885NSD2 4654/4885NSD3 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.